Metastatic renal cell carcinoma: past and present
Authors:
J. Novotný
Authors‘ workplace:
Institut klinické a experimentální medicíny, Praha
Published in:
Prakt. Lék. 2022; 102(3): 145-150
Category:
Of different specialties
Overview
The breakthroug novel treatments including immunoherapy (nivolumab, pembrolizumab, ipilimumab, avelumab, atezolizumab) and low molecular weight targeted therapy (such as axitinib, cabozantinib) have been introduced into the treatment of renal cancer in recent years. The result of these advances is the fact that a large proportion of patients are long-term survivivors. Current randomized clinical trials with these drugs are broadly discussed in this article.
Keywords:
renal carcinoma – immunotherapy – targeted therapy – PD-1 inhibitor – PD-L1 inhibitor
Sources
1. Maruschke M, Aristotelis G, Anastasiadis, et al. Hakenberg Spontaneous regression of renal cell carcinoma: Reality or myth? World J Clin Urol 2014; 24: 201–208.
2. Coppin C, Porzsolt F, Kumpf J, et al. Immunotherapy for advance renall cell cancer. Cochrane Database System Rev 2005; 1: CD001425.
3. Amin A, White RL. Interleukin-2 in Renal Cell Carcinoma: A hasbeen or a still-viable option? J Kidney Cancer VHL 2014; 1(7): 74–83.
4. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renall cell carcinoma. J Clin Oncol 2009; 27: 3584–3590.
5. Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 2013; 369: 722–731.
6. Escudier B, Szczylik C, Hutson ET. Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27(8): 1280–1289.
7. Rini BI, Halabi S, Rosenberg JE, et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 2010; 28: 2137–2143.
8. Escudier B, Bellmunt J, Negrier S, et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 2010; 28: 2144–2150.
9. Hudes G, Garducci M, Tomczak P, et al. Temsirolimus, interferon Alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271–2281.
10. George DJ, Hessel C, Halabi S, et al. Cabozantinib versus sunitinib for untreated patients with advanced renal cell carcinoma of intermediate or poor risk: subgroup analysis of the Alliance A031203 CABOSUN trial. Oncologist 2019; 24(11): 1497–1501.
11. Motzer RJ, Rini BI, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol 2019; 20(10): 1370–1385.
12. Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2019; 380: 1116–1127.
13. Rini BI, Powles T, Atkins MB, et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet 2019; 393: 2404–2415.
14. Motzer RJ, Penkov K, Haanen J, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2019; 380: 1103–1111.
Labels
General practitioner for children and adolescents General practitioner for adultsArticle was published in
General Practitioner
2022 Issue 3
Most read in this issue
- Giardiasis, one of the most important parasitic diseases in the world
- Lung cancer and its screening from the perspective of a general practitioner
- Patients with medically unexplained symptoms in general practice
- Problematics of administration of risky medicinal products by the general nurse